Skip to main content

Aciclovir 250mg powder for solution for infusion (Wockhardt, UK)

Section 19A approved medicine
Aciclovir 250mg powder for solution for infusion (Wockhardt, UK)
Section 19A approval holder
Pro Pharmaceuticals Group Pty Ltd ABN ​20 605 457 430
Phone
1300 077 674
Approved until
Status
Current
Medicines in short supply/unavailable
DBL Aciclovir 250mg/10mL Intravenous infusion injection vial - ARTG 56809
Indication(s)

Aciclovir intravenous infusion is indicated for the purpose of:  

  • Promoting resolution of acute clinical manifestations of mucocutaneous Herpes simplex virus infections in immunocompromised patients. 
  • Treatment of severe first episode primary or non-primary genital herpes in immune competent patients. 
  • Treatment of acute manifestations of Varicella zoster virus infection in immunocompromised patients. 
  • Treatment of shingles (Varicella zoster virus infection) in immune competent patients who show very severe acute local or systemic manifestations of the disease. Benefits can be expected in patients with rash duration shorter than 72 hours. The use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles.  
  • Treatment of Herpes simplex encephalitis.
Images
Picture of Aciclovir 250mg powder for solution for infusion - carton

Help us improve the Therapeutic Goods Administration site